Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Polydex Pharmaceuticals Limited POLXF OTC

Other OTC • Healthcare • Biotechnology • CA • USD

SharesGrow Score
15/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Polydex Pharmaceuticals Limited (POLXF) is a Biotechnology company in the Healthcare sector, currently trading at $1.99. It has a SharesGrow Score of 14/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $4M, -11.6%/yr average growth. Net income is $2M (loss), growing at -119.2%/yr. Net profit margin is -49.1% (negative). Gross margin is -2% (-14.8 pp trend).

Balance sheet: total debt is $1M against $3M equity (Debt-to-Equity (D/E) ratio 0.33, conservative). Current ratio is 1.26 (adequate). Debt-to-assets is 19.8%. Total assets: $6M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 0/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

POLXF SharesGrow Score Overview

25/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 0/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — POLXF

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
POLXF: -11.6%/yr revenue is, -119.2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet POLXF: Debt-to-Equity (D/E) ratio 0.33 (conservative), Current ratio is 1.26 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
—
MOAT N/A
N/A
No analyst coverage available for this stock.
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
POLXF: Net profit margin is -49.1%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.55-2.01
Volume1K
Avg Volume (30D)5.53K
Market Cap$6.82M
Beta (1Y)0.45
Share Statistics
IPO Date1983-03-14
Employees20
CEOGeorge G. Usher
Financial Highlights & Ratios
Revenue (TTM)$4.48M
Gross Profit$-91.73K
EBITDA$-745.93K
Net Income$-2.2M
Operating Income$-1.18M
Total Cash$375K
Total Debt$1.14M
Net Debt$1.13M
Total Assets$5.75M
Price / Sales (P/S)1.52
Analyst Forecast
Company Info
CountryCA
ExchangeOther OTC
CurrencyUSD

Price Chart

Track all markets on TradingView
POLXF
Polydex Pharmaceuticals Limited ↗  ·  Other OTC
Healthcare • Biotechnology
0.55 52WK RANGE 2.01

People Also View

ICCC
ICCC
ImmuCell Corporation
$7.60
-1.68%
 SNT
SNT
Senstar Technologies Ltd.
$2.94
+0.68%
 NAII
NAII
Natural Alternatives International, Inc.
$2.69
-2.18%
 PGNT
PGNT
Paragon Technologies, Inc.
$4.85
+0.00%
 PHLI
PHLI
PacificHealth Laboratories, Inc.
$0.00
+9,900.00%
 LLY
LLY
Eli Lilly and Company
$905.13
-1.88%
 JNJ
JNJ
Johnson & Johnson
$238.67
-0.60%
 ABBV
ABBV
AbbVie Inc.
$208.43
-0.87%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message